99mTc-p5+14 Imaging for Amyloidosis
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have received heparin or similar drugs within seven days before the study.
What data supports the effectiveness of the treatment 99mTc-p5+14 for amyloidosis?
Is 99mTc-p5+14 generally safe for humans?
How is the 99mTc-p5+14 treatment different from other treatments for amyloidosis?
The 99mTc-p5+14 treatment is unique because it uses a radiolabeled peptide for SPECT imaging to detect amyloid deposits in the body, offering a non-invasive way to visualize and diagnose systemic amyloidosis. Unlike other methods, it can bind to all types of amyloid, providing a comprehensive assessment of the disease's presence and distribution.1451112
What is the purpose of this trial?
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.
Research Team
Jonathan S Wall, PhD
Principal Investigator
University of Tennessee Graduate School of Medicine
Eligibility Criteria
This trial is for adults over 18 with confirmed systemic AL or ATTR amyloidosis, particularly affecting the heart. Participants must be in good health, understand and consent to study procedures, and women of childbearing potential must test negative for pregnancy. Exclusions include severe allergies, certain heart conditions, liver issues, claustrophobia preventing imaging protocol completion, dialysis patients, pregnant or breastfeeding individuals.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single IV dose of 99mTc-p5+14 and undergo imaging to evaluate dosimetry and biodistribution
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- 99mTc-p5+14
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Tennessee Graduate School of Medicine
Lead Sponsor
Attralus, Inc.
Industry Sponsor